How Placebos Change the Patient's Brain
Top Cited Papers
- 30 June 2010
- journal article
- review article
- Published by Springer Nature in Neuropsychopharmacology
- Vol. 36 (1) , 339-354
- https://doi.org/10.1038/npp.2010.81
Abstract
Although placebos have long been considered a nuisance in clinical research, today they represent an active and productive field of research and, because of the involvement of many mechanisms, the study of the placebo effect can actually be viewed as a melting pot of concepts and ideas for neuroscience. Indeed, there exists not a single but many placebo effects, with different mechanisms and in different systems, medical conditions, and therapeutic interventions. For example, brain mechanisms of expectation, anxiety, and reward are all involved, as well as a variety of learning phenomena, such as Pavlovian conditioning, cognitive, and social learning. There is also some experimental evidence of different genetic variants in placebo responsiveness. The most productive models to better understand the neurobiology of the placebo effect are pain and Parkinson's disease. In these medical conditions, the neural networks that are involved have been identified: that is, the opioidergic–cholecystokinergic–dopaminergic modulatory network in pain and part of the basal ganglia circuitry in Parkinson's disease. Important clinical implications emerge from these recent advances in placebo research. First, as the placebo effect is basically a psychosocial context effect, these data indicate that different social stimuli, such as words and rituals of the therapeutic act, may change the chemistry and circuitry of the patient's brain. Second, the mechanisms that are activated by placebos are the same as those activated by drugs, which suggests a cognitive/affective interference with drug action. Third, if prefrontal functioning is impaired, placebo responses are reduced or totally lacking, as occurs in dementia of the Alzheimer's type.Keywords
This publication has 120 references indexed in Scilit:
- Biological, clinical, and ethical advances of placebo effectsPublished by Elsevier ,2010
- Electrophysiological properties of thalamic, subthalamic and nigral neurons during the anti‐parkinsonian placebo responseThe Journal of Physiology, 2009
- Neuropathic pain is maintained by brainstem neurons co-expressing opioid and cholecystokinin receptorsBrain, 2008
- New Insights into the Placebo and Nocebo ResponsesNeuron, 2008
- Placebo effects on human μ-opioid activity during painProceedings of the National Academy of Sciences, 2007
- Overt versus covert treatment for pain, anxiety, and Parkinson's diseaseThe Lancet Neurology, 2004
- Placebo-responsive Parkinson patients show decreased activity in single neurons of subthalamic nucleusNature Neuroscience, 2004
- Open versus hidden medical treatments: The patient's knowledge about a therapy affects the therapy outcome.Prevention & Treatment, 2003
- Placebo and Opioid Analgesia-- Imaging a Shared Neuronal NetworkScience, 2002
- THE MECHANISM OF PLACEBO ANALGESIAThe Lancet, 1978